REGN Regeneron (REGN) Q4 FY24 earnings call
Regeneron concluded Q4 FY24 with robust financial performance, driven by strong growth in Dupixent and Libtayo, alongside increasing uptake of EYLEA HD. The company is strategically investing in its broad pipeline, with several key regulatory approvals and pivotal data readouts anticipated in 2025, while also enhancing shareholder returns through a new dividend and increased share repurchase authorization. Management expressed confidence in the long-term growth of the business and the innovative R&D engine.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
REGN operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Patients DUPIXENT | 1.4M+DUPIXENT is currently the most widely used innovative branded antibody medicine with more than 1.4 million patients on therapy globally.Source: earnings call transcript | 1.4M+Turning to DUPIXENT, which continues to transform the lives of more than 1.4 million patients worldwide with type 2 inflammatory diseases that are currently on treatment.Source: earnings call transcript | 1.5M+Turning to Dupixen, which continues to deliver significant patient benefit to patients globally with more than 1.5 million patients actively treated worldwide, Dupixen has had a tremendous impact across these 9 approved indications, and it is the #1 biologic medicine prescribed by dermatologists and pulmonologist, allergists and ENTs, Second quarter net sales were $6 billion, reflects 38% growth on a constant currency basis and the US, sales grew 42% year-over-year to $4.6 billion, primarily driven by continued growth across our blockbuster indications and uptake in recent launches.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.